Last reviewed · How we verify
NCT04187625: CTKD
Cell-based Therapy for the Treatment of Kidney Disease
EARLY_PHASE1 trial testing endothelial progenitor cell in Kidney Diseases in 10 participants. Status unknown.
1 January 2024
Quick facts
| Lead sponsor | Brigham and Women's Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 January 2023 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 May 2025 |
Drugs / interventions tested
- endothelial progenitor cell — full drug profile →
Conditions studied
- Kidney Diseases — all drugs for Kidney Diseases →
Sponsor
Brigham and Women's Hospital
Who can join
Adults 18 to 85, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04187625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Diseases
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting
Other Brigham and Women's Hospital trials
Trials by the same sponsor.
- NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
- NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
- NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
- NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
- NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04187625 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
- Last refreshed: 26 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing